CD20-positive T-cell lymphoma involving bone marrow: report of four cases | SpringerLink
Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i)... | Download Scientific Diagram
Cells | Free Full-Text | Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models | Science Translational Medicine
CD3xCD20 bsAb - Protheragen
Frontiers | A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?: Molecular Therapy
A, B Lymphocyte markers (CD3 and CD20) on the skin of individuals... | Download Scientific Diagram
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome | Nature Reviews Clinical Oncology
Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i)... | Download Scientific Diagram
Antibody drug development: Targeting CD20 and CD3
Targeting CD20 and CD3, the witness and creator in the process of antibody drug development - ACROBiosystems
Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
CD20 expression and localization on WT Ramos B cells. (A) Flow... | Download Scientific Diagram
Alexa Fluor 700 Anti-Human CD20, B-Ly1 | SouthernBiotech
Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy | Scientific Reports
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies | Nature Reviews Neurology
Diagnostics | Free Full-Text | Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review
Cancers | Free Full-Text | Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing - eBioMedicine
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys | Scientific Reports
